関連する実験動画
Updated: Jun 30, 2025

07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
84.9K
癌細胞における低酸素反応シグナル伝達を妨害する低酸素誘導因子1および2のサイクルペプチド阻害剤の特定と開発
Andrew T Ball1, Soran Mohammed1, Cyrielle Doigneaux1
1School of Chemistry, University of Southampton, Southampton SO17 1BJ, U.K.
Journal of the American Chemical Society
|March 19, 2024
まとめ
研究者は,HIF-αとHIF-βの相互作用を阻害することによって,低酸素誘導因子 (HIF) を抑制するサイクルペプチドを開発しました. このHIFシグナル伝達障害は 低酸素腫瘍を標的とした新たながん治療戦略を提示する可能性がある.
科学分野:
- 分子生物学
- 癌 研究
- 薬物の発見
背景:
- 低酸素誘導因子 (HIF) は酸素不足に対する細胞の適応を調節する.
- HIFは低酸素の微小環境で腫瘍の生存と成長に不可欠です.
- HIFを抑制することは,がん治療の潜在的な治療戦略です.
研究 の 目的:
- HIF-1およびHIF-2転写因子を阻害する周期性ペプチドを特定し,特徴づけること.
- HIF-αとHIF-βサブユニットの相互作用を妨害する.
- がん細胞における低酸素反応シグナル伝達におけるこれらの阻害剤の有効性を評価する.
主な方法:
- サイクルペプチド阻害剤の特定と最適化
- HIF-αへのペプチド結合の特徴
- HIF-α/HIF-βのタンパク質相互作用の障害の評価
- がん細胞系における低酸素反応シグナル伝達障害の評価
主要な成果:
- 一連の周期性ペプチドが特定され,最適化されました.
- これらのペプチドはHIF-αと結合し,HIF-βとの相互作用を抑制する.
- 鉛分子は複数の癌細胞系における 低酸素反応のシグナル伝達を 効果的に妨害しました
結論:
- 循環性ペプチドは,HIF- 1とHIF- 2の機能を効果的に抑制することができます.
- HIF-α/HIF-βの相互作用を妨害することは,低毒性がんを標的とする有効な戦略です.
- 開発された鉛分子は 潜在的な抗癌療法として有望です
関連する概念動画
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K

